Mean Lesion Size Research Articles

18F]FDG PET/CT versus Dynamic Contrast-Enhanced CT for the diagnosis of solitary pulmonary Nodule: A Head-to-Head comparative Meta-Analysis.

This head-to-head comparative meta-analysis aimed to evaluate the comparative diagnostic efficacy of [18F]FDG PET/CT and dynamic contrast-enhanced CT(DCE-CT) for the differentiation between malignant and benign pulmonary nodules. An extensive search was conducted in the PubMed, Embase, and Web of Science to identify available publications up to March 23, 2024. Studies were included if they evaluated the diagnostic efficacy of [18F]FDG PET/CT and DCE-CT for the characterization of pulmonary nodules. Sensitivity and specificity were assessed using the inverse variance method, followed by transformation via the Freeman-Tukey double inverse sine transformation. The quality of the included studies utilizing the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool. Seven articles involving 1,183 patients were included in the meta-analysis. The sensitivity of [18F]FDG PET/CT was comparable to that of DCE-CT (0.88 vs. 0.87, P = 0.95). Similarly, the specificity of [18F]FDG PET/CT was not significantly different from that of DCE-CT (0.63 vs. 0.54, P = 0.47). No significant publication bias was detected for any outcome (Egger's test: all P > 0.05). For DCE-CT, meta-regression analysis identified the mean lesion size of pulmonary nodules (<20mm vs.≥20mm, P=0.01) as a potential source of heterogeneity. Meanwhile, the number of patients (<100 vs.≥100, P<0.01) for PET/CT may also contribute to the heterogeneity. Our meta-analysis indicates that [18F]FDG PET/CT demonstrates similar sensitivity and specificity to DCE-CT for the diagnosis of pulmonary nodules. However, the number of the head-to-head studies were relatively small, further larger sample prospective research is required to confirm these findings.

Virtual bronchoscopic navigation and guided radial endobronchial ultrasound for peripheral pulmonary lesions: harmonizing modalities to optimize accuracy.

Peripheral pulmonary lesions (PPLs) present a significant diagnostic challenge due to their location beyond the reach of traditional bronchoscopy. With lung cancer being the leading cause of cancer-related mortality worldwide, accurate and early diagnosis of PPLs is crucial. Virtual bronchoscopic navigation (VBN) combined with radial endobronchial ultrasound (R-EBUS) has emerged as a promising technique to enhance the diagnostic yield for these lesions. This retrospective observational study evaluated the diagnostic yield of VBN-guided R-EBUS in patients with PPLs identified on computed tomography. The study included nine patients who underwent VBN-guided R-EBUS biopsy sampling. Patient demographics, lesion characteristics, and procedural outcomes were analyzed using descriptive and inferential statistics. The mean age of the patients was 57.33 years, with a mean lesion size of 3.24 cm. The diagnostic yield of VBN-guided R-EBUS was 77.7% (95% confidence interval: 68.5-85.8%). Non-small cell carcinoma was the most frequent histopathological diagnosis (55.5%). Complications included bleeding in two patients (22.2%) and bronchospasm in one patient (11.1%), all managed conservatively. VBN-guided R-EBUS provides high diagnostic accuracy and a low risk of complications in patients with PPLs.

Role of macroscopic on-site evaluation of endoscopic ultrasound-guided fine-needle aspiration/biopsy: Results of a multicentric prospective study.

The concept of macroscopic on-site evaluation (MOSE) was introduced in 2015 when the endoscopist observed better diagnostic yield when the macroscopically visible core on MOSE was superior to 4 mm. Recent studies suggest that MOSE by the endoscopist may be an excellent alternative to rapid on-site evaluation, and some classifications have been published. Few studies have assessed the adequacy of histologic cores in MOSE during endoscopic ultrasound-guided fine-needle aspiration/biopsy (EUS-FNA/FNB). To evaluate the performance of MOSE during EUS-FNA/FNB. This multicentric prospective study was conducted in 16 centers in 3 countries (Egypt, Iraq, and Morocco) and included 1108 patients with pancreatic, biliary, or gastrointestinal pathology who were referred for EUS examination. We prospectively analyzed the MOSE in 1008 patients with available histopathological reports according to 2 classifications to determine the adequacy of the histological core samples. Data management and analysis were performed using a Statistical Package for Social Sciences (SPSS) version 27. A total of 1074 solid lesions were biopsied in 1008 patients with available cytopathological reports. Mean age was 59 years, and 509 patients (50.5%) were male. The mean lesion size was 38 mm. The most frequently utilized needles were FNB-Franseen (74.5%) and 22 G (93.4%), with a median of 2 passes. According to 2 classifications, 618 non-bloody cores (61.3%) and 964 good samples (95.6%) were adequate for histological evaluation. The overall diagnostic yield of cytopathology was 95.5%. The cytological examination confirmed the diagnosis of malignancy in 861 patients (85.4%), while 45 samples (4.5%) were inconclusive. Post-procedural adverse events occurred in 33 patients (3.3%). Statistical analysis showed a difference between needle types (P = 0.035) with a high sensitivity of FNB (97%). The analysis of the relationship between the MOSE-score and the final diagnosis showed a significant difference between the different scores of the MOSE (P < 0.001). MOSE is a simple method that allows endoscopists to increase needle passes to improve sample quality. There is significantly higher FNB sensitivity and cytopathology diagnostic yield with good MOSE cores.

Feasibility of endoscopic submucosal dissection including papilla (with video).

Endoscopic papillectomy (EP) is a low-invasive treatment for duodenal tumors including papilla. The limit of lesion size and local recurrence have been issues in EP. We developed endoscopic submucosal dissection (ESD) for the duodenal tumors including papilla (ESDIP: ESD including papilla) to overcome the problems. The aim of this study was to evaluate the feasibility of ESDIP. We included the patients who underwent ESDIP from August 2010 to January 2024 in this study. We evaluated the retrospective characteristics of patients and lesions, clinical results of ESDIP and of endoscopic retrograde cholangiopancreatography (ERCP) as prevention for delayed adverse events, and pathological findings. We also calculated the cumulative recurrence rate and overall survival rate at 12 months after ESDIP. Fifty-four patients were included in this study. The mean lesion size was 39 mm. The third-quarter cases revealed a less than half-circumferential lesion, and the one case with a full-circumferential lesion. Resection was accomplished in 96% (n = 52), and also the en-bloc resection rate was 96%. Of the cases in accomplished resection, 98% of patients were intubated with a pancreaticobiliary drainage tube by ERCP. Intraprocedural perforation occurred in eight cases. Delayed bleeding occurred in 10 cases. Delayed perforation was seen only in one case. The incidence of post-ERCP pancreatitis was 25%. Cumulative local recurrence rate and the overall survival rate were 15% and 96%, respectively. ESDIP may be feasible for duodenal tumors including papilla, and is a potential alternative option to avoid pancreaticoduodenectomy.

Outcomes Following Autologous Osteochondral Transplantation for Osteochondral Lesions of the Talus at 10-Year Follow-Up: A Retrospective Review.

The purpose of this study was to evaluate outcomes following autologous osteochondral transplantation (AOT) for the treatment of osteochondral lesions of the talus (OLT) at a minimum of 10-year follow-up. Retrospective chart review identified patients who underwent AOT for the treatment of OLT. Pre-operative magnetic resonance imaging (MRI) scans were obtained in all patients. Clinical outcomes assessed included: pre- and post-operative foot and ankle outcome score (FAOS), visual analog scale (VAS), patient satisfaction, complications, failures and secondary surgical procedures. Thirty-nine patients with a mean lesion size was 122.3 ± 64.1 mm2 and mean follow-up time of 138.9 ± 16.9 months were included. The mean FAOS scores improved from a preoperative score of 51.9 ± 16.0 to 75.3 ± 21.9 (P < 0.001). Increasing lesion size was variable associated with inferior FAOS scores (R2 = 0.2228). There was statistically significant higher mean T2 relaxation values at the superficial layer at the site of the AOT graft (42.9 ± 5.2 ms) compared to the superficial layer of the adjacent native cartilage (35.8 ± 3.8 ms) (P < 0.001). Seventeen complications (43.6%) were observed, the most common of which was anterior ankle impingement (25.6%). There were 2 failures (5.1%), both of which had a history of prior bone marrow stimulation via microfracture and post-operative cysts identified on MRI. This retrospective review found that AOT for the treatment of large OLTs produced a 94.9% survival rate at a minimum of 10-year follow-up. Increasing lesion size was associated with inferior clinical outcomes. The findings of this study indicates that AOT is a viable long-term surgical strategy for the treatment of large OLTs.

Is the BioSentry Tract Sealant System Effective in Reducing the Pneumothorax Rate After CT-Guided Transthoracic Lung Biopsy With an 18G Biopsy Needle?

This study evaluated whether the BioSentry Tract Sealant System (BTS) (Merit Medical Systems, South Jordan, Utah) reduces pneumothorax rates in CT-guided lung biopsies (CTLB) using an 18G biopsy/17G introducer needle. A total of 272 patients underwent CTLB between January 2015 and February 2019 using a 17G/18G system. BTS was used in 125 patients, while no pleural sealant was used in 147. The variables assessed included pneumothorax on post-biopsy CT images or chest X-ray, chest tube insertion, lesion size, pleura-to-lesion distance, and the presence of emphysema. The two groups were compared using T-tests with a significance level of 0.05. In the BTS group, 23 subjects (18%) had a pneumothorax compared to 38 (26%) in the control group (p < 0.05). Four patients (17%) in the BTS group required a chest tube, compared to three patients (8%) in the control group (p = 0.28). The mean lesion size in patients with a pneumothorax was 1.62 cm in the BTS group and 2.44 cm in the control group (p = 0.27). The mean pleura-to-lesion distance in those with pneumothorax was 2.23 cm in the BTS group and 1.52 cm in the control group (p = 0.17). Emphysema was present in 47% of patients in the BTS group and 30% in the control group (p < 0.05). BTS reduced pneumothorax rates in CTLB patients using a 17G/18G system, despite a higher proportion of emphysema patients in the BTS group. No significant difference in the rate of chest tube insertion was observed with or without BTS, which contrasts with previous studies where 19G/20G biopsy systems were used.

Debulking surgery prior to stereotactic radiotherapy for head and neck paragangliomas.

Surgery has been used as standard treatment for head and neck paragangliomas. Stereotactic radiotherapy (SRT) has also been increasingly used for this disease. The results for combined modality are not well described. This analysis aims to describe the results for combined modality of debulking surgery and SRT for head and neck paragangliomas (HNP). Retrospective cohort of patients treated in a large university hospital between 2008 and 2023. Fifty-one patients had their charts reviewed. Mean age was 56.3 years. Most were female (82.3%). Most lesions arose from the skull-base (84.3%) and not the inner ear. Most lesions were larger than 3 cm (51.0%) and mean lesion size was 4.4 cm. 36 (70.6%) were treated with radiotherapy alone while 15 (29.4%) were treated with combined modality treatment. Median follow-up was 42.5 months (7.1-112.8 months). There were no reported deaths nor disease progression. Debulking surgery did not impact response rate for SRT (52.8% vs. 47.2% for SRT alone and debulking surgery, respectively, p = 0.971). There was no impact on new neurological deficits after SRT (25.0 vs. 13.3%, respectively, p = 0.356). Debulking surgery did not improve response rate for SRT. In our sample, it also did not impact new neurological deficits for SRT. Prospective data regarding HNP treatment is needed.

EUS-guided transesophageal fine-needle biopsy sampling of lung masses: diagnostic performance and safety

Pulmonary masses are a diagnostic challenge in the field of EUS tissue acquisition, especially through transesophageal EUS-guided fine-needle biopsy sampling (EUS-FNB). Our study evaluated the feasibility, diagnostic performance, and safety of EUS-FNB of pulmonary lesions. Fifty-three patients were enrolled in a prospective registry. All EUS procedures were performed by experienced endosonographers. Outcomes were specimen adequacy, diagnostic accuracy, diagnostic sensibility, diagnostic specificity, and safety. The mean patient age was 70 ± 10.4 years, and 71.7% were men. The mean lesion size was 52.4 ± 23.3mm, and patients mostly had a single lesion (86.8%). Most patients had an advanced stage at diagnosis (stage IV, 41.82%), and the most common lung cancer was non-small cell lung carcinoma (69.4%). The diagnostic adequacy rate was 92.86%, and diagnostic accuracy was 87.5%. Adverse events were reported in 3 procedures. Transesophageal EUS-FNB is a feasible and safe diagnostic method of tissue sampling for lung masses reachable by EUS.

Outcomes Following Autologous Osteochondral Transplantation for Osteochondral Lesions of the Talus at A Minimum of 10-Year Follow-Up: A Retrospective Review

Category: Ankle; Sports Introduction/Purpose: The purpose of this study was to evaluate outcomes following autologous osteochondral transplantation (AOT) for the treatment of osteochondral lesions of the talus (OLT) at a minimum of 10-year follow-up. Methods: Retrospective chart review identified patients who underwent AOT for the treatment of OLT. Pre-operative magnetic resonance imaging (MRI) scans were obtained in all patients. Clinical outcomes assessed included: pre- and post-operative foot and ankle outcome score (FAOS), visual analog scale (VAS), patient satisfaction, complications, failures and secondary surgical procedures. Results: Thirty-nine patients with a mean lesion size was 122.3±64.1 mm2 and mean follow-up time of 138.9±16.9months were included. The mean FAOS scores improved from a preoperative score of 51.9±16.0 to 75.3±21.9 (p &lt; 0.001). Increasing lesion size was variable associated with inferior FAOS scores (R2=0.2228). There was statistically significant higher mean T2 relaxation values at the superficial layer at the site of the AOT graft (42.9±5.2ms) compared to the superficial layer of the adjacent native cartilage (35.8±3.8ms) (p &lt; 0.001). Seventeen complications (43.6%) were observed, the most common of which was anterior ankle impingement (25.6%). There were 2 failures (5.1%), both of which had a history of prior bone marrow stimulation via microfracture and post-operative cysts identified on MRI. Conclusion: This retrospective review found that AOT for the treatment of large OLTs produced a 94.9% survival rate at a minimum of 10-year follow-up. Increasing lesion size was associated with inferior clinical outcomes. The findings of this study indicates that AOT is a viable long-term surgical strategy for the treatment of large OLTs.

Osteochondral Lesions of the 1st Metatarsal Head: A Systematic Review

Category: Midfoot/Forefoot; Other Introduction/Purpose: The purpose of this systematic review was to evaluate outcomes following surgical intervention for osteochondral lesions of the 1st metatarsal head. Methods: During February 2024, the PubMed, Embase and Cochrane library databases were systematically reviewed to identify clinical studies examining outcomes following surgical intervention for the management of osteochondral lesions of the 1st metatarsal head. Data regarding study characteristics, patient demographics, subjective clinical outcomes, radiological outcomes, complications, and failure rates were extracted and analyzed. In addition, the level of evidence and quality of evidence for each individual study was also assessed. Fifteen studies were included. Results: In total, 324 patients (367 metatarsal) underwent surgical intervention for a 1st metatarsal OCL at a weighted mean follow-up time of 32.1±9.2 months. The mean lesion size was 52.3 ± 8.4 mm2. The most common procedure was osteochondral autograft in 123 cases (19.4%). Other procedures performed included subchondral drilling, particulated juvenile cartilage allograft, osteochondral mosaicplasty, microfracture and anterograde drilling. There were statistically significant improvements in subjective clinical outcomes across all surgical techniques. The overall complication rate was 2.2%, the most common of which was persistent pain (1.5%). There were 29 failures (8.9%) all of which warranted a further surgical procedure. Conclusion: This systematic review demonstrated that osteochondral lesions of the 1st metatarsal head are an uncommon pathology with no consensus regarding the optimal treatment strategy. The most common surgical procedure (osteochondral autograft) restores the osteochondral unit, leading to excellent clinical outcomes at final follow-up. Microfracture destroys the subchondral plate and produces inferior quality fibrocartilage, thus should not be recommended.

Rationale of restaging transurethral resection of bladder tumor in patients with nonmuscle invasive bladder cancer in the current era.

We present retrospective data of patients with nonmuscle invasive bladder cancer (NMIBC) who underwent restaging transurethral resection of bladder tumor (Re-TURBT) at a tertiary care center. Records of all NMIBC patients undergoing Re-TURBT between March 2021 and September 2023 were retrospectively analyzed. Patients were risk stratified based on TURBT pathology. Re-TURBT was performed between 4 and 6 weeks. Adverse features such as number, size, and appearance were noted. Patients with persistent disease at Re-TURBT were counseled for early cystectomy with urinary diversion or intravesical Bacillus Calmette-Guerin (BCG). In case of disease upstaging, patients were counseled for radical cystectomy. Thirty-eight NMIBC patients (30 males and 8 females) underwent Re-TURBT. Six patients had residual/persistent disease at 6 weeks, all high risk and high grade (HG, P value not significant, P = 0.31). There was no association with number and appearance of tumors with residual/persistence at 6 weeks. The mean lesion size on imaging in cases with and without residual disease was 3.32 ± 0.86 versus 3.39 ± 0.92 cm, respectively, P value not significant (0.868). There was no residual disease in the low-grade (LG) pT1 group, but HG pTa and pT1 (n = 3) had residual disease. Four HG pT1 patients opted for early cystectomy. Two patients each had pT0 and two pT2. At 3 months of follow-up, urethral strictures were seen both in high risk and intermediate risk. Among four patients who had stricture, meatal stenosis was common (50%, n = 2). Two patients had long-segment stricture requiring perineal urethrostomy with stage I Johannsen repair. All HG pT1 lesion patients eventually underwent cystectomy (3 were under staged and two treated completely with TURBT, one with TURBT + BCG and one patient progressed to metastasis). Re-TURBT is essential for the management of HG pTa and HG pT1 lesions for accurate staging and treatment of residual disease. However, LG pT1 patients can safely be excluded from Re-TURBT.

Endoscopic ultrasound-guided fine needle biopsy using macroscopic on-site evaluation technique reduces the number passes yet maintains a high diagnostic accuracy: A randomized study.

Although rapid on-site cytological evaluation (ROSE) for endoscopic ultrasound (EUS)-guided tissue acquisition (EUS-TA) may increase diagnostic yield, it is not widely available. Macroscopic on-site evaluation (MOSE) is an alternative modality although it is not standardized for EUS-guided fine-needle biopsy (FNB). We evaluated diagnostic performance of MOSE compared with conventional technique of EUS-TA using core biopsy needle. Consecutive patients undergoing EUS-FNA for solid lesions were randomized to MOSE or conventional arms. The primary and secondary outcome measures were diagnostic accuracy, diagnostic yield, sensitivity, specificity, positive and negative predictive values, and the number of passes, respectively. The optimum parameters for macroscopic visible core (MVC, i.e., length, number) by MOSE to achieve accurate diagnosis were evaluated. Ninety-six patients (48 conventional and 48 MOSE) were enrolled. Mean lesion size was larger in MOSE arm (32.67±7.22 vs 29.31±6.98mm, P=0.023). Diagnostic accuracy (95.8% vs 91.6%), diagnostic yield (97.9% vs 95.8%), procedure duration, and adverse events of the two methods were similar. Median number of passes with MOSE was less (2 vs 3 P=0.000). Area under the receiver operating characteristic curve showed that with MOSE, obtaining a total MVC length of 11.5mm had 93.3% sensitivity, and 2.5 MVC cores (each 4mm) had 86.7% sensitivity for malignancy diagnosis. EUS-FNB with MOSE, a simple reliable technique, can achieve a high and comparable diagnostic accuracy with lesser number of passes. Obtaining longer length and greater number of MVC increase the sensitivity to diagnose malignancy with MOSE.

Conservative Treatment of Chalazion in Pediatric Patients.

This study aims to assess the effectiveness of conservative treatment for chalazion in pediatric patients. The authors retrospectively reviewed 101 chalazions in 91 children aged younger than 15 years at the authors' clinic. Patients were divided into 3 groups by their ages at the time of conservative or surgical treatment: 30 patients aged 2 and under (group A), 38 patients aged 3 to 6 (group B), and 23 patients aged 7 to 15 (group C). Initially, conservative treatment was administered, then incision and curettage were performed if it proved ineffective. Data included sex, age, number of lesions, position of lesions, size of lesions, time to resolution after treatment, and presence of complications for each group; comparative analysis was conducted. The success rate of conservative treatment was 85.7% (78/91): 96.7% (29/30) in group A, 86.8% (33/38) in group B, and 69.7% (16/23) in group C (P = 0.022). The mean age of the patients and the mean lesion size showed a significant difference between the conservative group and the surgery group (P = 0.047 and 0.009, respectively). Conservative treatment of chalazion is an effective first-line treatment option for uncomplicated and small chalazion in pediatric patients. The authors should consider starting patients on a trial of conservative therapy versus invasive therapy based on the size of the lesion, the duration of conservative treatment, and age.

Use of Snare Tip Endoscopic Submucosal Dissection in the Endoluminal Management of Complex Colon Lesions.

Endoscopic submucosal dissection for advanced colon lesions is typically performed with specialized and costly endoscopic knives, potentially limiting accessibility and increasing procedural cost. Alternatively, the tip of an endoscopic snare, which is inexpensive and universally available, has demonstrated safe and efficient use in gastric lesions but lacks sufficient data for use in colon lesions. This study aimed to assess patient outcomes after endoscopic submucosal dissection of advanced colon lesions using the endoscopic snare tip. A retrospective review of a prospectively maintained database at a single tertiary care center was conducted. This study was conducted at a single tertiary care center. Adult patients with colon lesions that were not amenable to snare polypectomy were evaluated for endoscopic submucosal dissection. Snare tip resection was performed in select patients with lesions that were lifted adequately after submucosal injection. Patients who underwent hybrid resections with endoscopic mucosal dissection were excluded. En bloc resection rates, operative time, perioperative complications, and short-term outcomes, such as length of stay and lesion recurrence on follow-up colonoscopy, were evaluated. A total of 121 patients underwent snare tip endoscopic submucosal dissection, with a mean lesion size of 28.8 ± 9.84 mm. Most procedures were performed in the endoscopy suite (81.8%). The en bloc resection rate was 81.8%, with an average procedure time of 37.1 ± 29.8 minutes. There were 2 perforations (1.70%), one of which was managed operatively. Recurrence occurred in 6 patients (7.89%) at the time of follow-up colonoscopy. This study was retrospective, conducted by 2 skilled endoscopists with experience in endoscopic resection, and had short-term follow-up. Snare tip endoscopic submucosal dissection for advanced colon lesions demonstrates satisfactory short-term outcomes, suggesting its potential as a safe and accessible alternative to specialized knives, thereby possibly enhancing the adoption of endoscopic resection and improving patient accessibility. See Video Abstract . ANTECEDENTES:La disección submucosa endoscópica para lesiones avanzadas del colon generalmente se realiza con bisturíes endoscópicos especializados y costosos, lo que potencialmente limita la accesibilidad y aumenta el costo del procedimiento. Alternativamente, la punta de asa endoscópica, que es económica y está disponible universalmente, ha demostrado su uso seguro y eficiente en lesiones gástricas, pero carece de datos suficientes para su uso en lesiones de colon.OBJETIVO:Evaluar los resultados de los pacientes después de la disección submucosa endoscópica de lesiones avanzadas del colon utilizando la punta del asa endoscópica.DISEÑO:Revisión retrospectiva de una base de datos mantenida prospectivamente en un único centro de atención terciaria.AJUSTE:Estudio realizado en un único centro de atención terciaria.PACIENTES:Pacientes adultos con lesiones de colon no susceptibles a polipectomía con asa, fueron evaluados para disección submucosa endoscópica. La resección con punta del asa se realizó en pacientes seleccionados con lesiones que se levantaron adecuadamente después de la inyección submucosa. Se excluyeron pacientes sometidos a resecciones híbridas con disección endoscópica de la mucosa.PRINCIPALES MEDIDAS DE RESULTADO:Se evaluaron las tasas de resección en bloque, tiempo operatorio, complicaciones perioperatorias y resultados a corto plazo, como la duración de la estancia hospitalaria y la recurrencia de la lesión en la colonoscopia de seguimiento.RESULTADOS:Un total de 121 pacientes se sometieron a disección submucosa endoscópica con punta de asa, con un tamaño medio de lesión de 28,8 ± 9,84 mm. La mayoría de los procedimientos se realizaron en la sala de endoscopia (81,8%). La tasa de resección en bloque fue del 81,8% con un tiempo medio de procedimiento de 37,1 ± 29,8 min. Hubo dos perforaciones (1,70%), una de las cuales fue manejada quirúrgicamente. La recurrencia se observó en 6 pacientes (7,89%) durante la colonoscopia de seguimiento.LIMITACIONES:Estudio retrospectivo, realizado por dos endoscopistas expertos con experiencia en resección endoscópica y el seguimiento de corto plazo.CONCLUSIONES:La disección submucosa endoscópica con punta de asa para lesiones avanzadas del colon demuestra resultados satisfactorios a corto plazo, lo que sugiere su potencial como una alternativa segura y accesible a los bisturíes especializados, lo que posiblemente mejore la adopción de la resección endoscópica y la accesibilidad del paciente. (Traducción - Dr. Fidel Ruiz Healy ).

Endoscopic submucosal dissection and endoscopic mucosal resection for Barrett's-associated neoplasia: a systematic review and meta-analysis of the published literature.

The role of endoscopic submucosal dissection (ESD) in the treatment of Barrett esophagus-associated neoplasia (BEN) has been evolving. We examined the efficacy and safety of ESD and endoscopic mucosal resection (EMR) for BEN. A database search was performed for studies reporting efficacy and safety outcomes of ESD and EMR for BEN. Pooled proportional and comparative meta-analyses were performed. 47 studies (23 ESD, 19 EMR, 5 comparative) were included. The mean lesion sizes for ESD and EMR were 22.5 mm and 15.8 mm, respectively; most lesions were Paris type IIa. For ESD, pooled analysis showed rates of en bloc, R0, and curative resection, and local recurrence of 98%, 78%, 65%, and 2%, respectively. Complete eradication of dysplasia and intestinal metaplasia were achieved in 94% and 59% of cases, respectively. Pooled rates of perforation, intraprocedural bleeding, delayed bleeding, and stricture were 1%, 1%, 2%, and 10%, respectively. For EMR, pooled analysis showed rates of en bloc, R0, and curative resection, and local recurrence of 37%, 67%, 62%, and 6%, respectively. Complete eradication of dysplasia and intestinal metaplasia were achieved in 94% and 75% of cases. Pooled rates of perforation, intraprocedural bleeding, delayed bleeding, and stricture were 0.1%, 1%, 0.4%, and 8%, respectively. The mean procedure times for ESD and EMR were 113 and 22 minutes, respectively. Comparative analysis showed higher en bloc and R0 resection rates with ESD compared with EMR, with comparable adverse events. ESD and EMR can both be employed to treat BEN depending on lesion type and size, and center expertise.

Pathogenicity and Virulence‐Associated Factors of Pseudomonas syringae pv. syringae and [P. amygdali pv. morsprunorum] Strains From New Zealand Sweet Cherry (Prunus avium) Orchards

ABSTRACTPreviously genetically characterised strains of Pseudomonas syringae. pv. syringae (Pss), [P. amygdali pv. morsprunorum] (Pam, syn. P. s. pv. morsprunorum race 1) and Pseudomonas spp. from New Zealand were characterised for their pathogenicity and aggressiveness in plant tissue and associated virulence factors. Lesions on detached, Pss‐inoculated immature fruit increased rapidly in size and, at 10 days post inoculation (dpi), had larger areas under the disease progress curve (AUDPC) than Pam‐inoculated fruit (48.9 and 22.0, respectively). Detached leaves infiltrated with Pss‐developed symptoms within 1 dpi and from 2 dpi for Pam. Necrosis from most Pss strains extended into the leaf veins by 7 dpi, while Pam strains' necrosis was confined to the inoculation site. On detached 1‐year‐old cherry shoots, Pseudomonas spp. strains exhibited the smallest mean lesion size (2.1–2.4 mm), whereas larger mean lesion sizes were observed with Pss strains (5.7–13.7 mm) and Pam strains (3.9–14.0 mm). A functional T3SS was inferred for Pss and Pam strains based on the hypersensitivity reactions observed on tobacco leaves and symptoms elicited on cherry tissue. Syringomycin production was prevalent (88%) among Pss strains. In contrast, only 1.4% of Pam strains produced coronatine. Most Pss strains (97.0%) were able to catalyse ice formation. The coexistence of strains with varying degrees of virulence and non‐pathogenic strains suggests a complex ecological balance, where multiple factors, including genetic variation, virulence traits and environmental conditions, shape the population dynamics and disease outcomes.

A higher incidence of chondral injuries on the medial femoral condyle in concomitant ACL ruptures, no significant difference in treatment:A systematic review.

The associated damage to articular cartilage in anterior cruciate ligament (ACL) injured patients is a well-recognized phenomenon; however, there is a relative paucity in the literature regarding the different treatment techniques and outcomes. The purpose of this systematic review was to identify patients treated for acute ACL rupture and associated cartilage injury, with interest in the surgical management of these chondral injuries and any difference in patient-reported outcome measures (PROMs) differing techniques. A systematic review was performed looking for treatment or management of International Cartilage Repair Society grade 3 or 4 articular cartilage injury at the time of ACLreconstruction. Seventeen studies fit the criteria, a total of 892 patients were included, 64.6% were male with a mean age of 33.7and the average time to follow-up was 41.7 months. 68.2% of the lesions were on the medial femoral condyle (MFC) with a mean lesion size of 3.9 cm2. Six different operative methods of dealing with chondral lesions were identified, there was no significant difference in PROMs between the techniques, although there was a significant difference between the preoperative and postoperative outcome measures. The systematic review found that chondral defects on the MFC are more common in concomitant ACL injuries, despite the pattern of bone bruising being more common on the lateral femoral condyle as reported in the literature. It also found no significant difference in the PROMs between the six different techniques identified for the concomitant management of ACL reconstruction and chondral defects. Level II.

Non-Operating Room Anesthesia (NORA) for Ultrasound-Guided Liver Radiofrequency Ablation.

Percutaneous ultrasound-guided radiofrequency ablation (RFA) is a well-studied treatment option for locally non-advanced hepatocellular carcinoma (HCC) and colorectal liver metastases (CRLMs). Sedation is of crucial interest as it enables safe and pain-free procedures. Whether the type of sedation has an impact on procedural outcome is still not well investigated. We retrospectively collected data on patients undergoing liver RFA for various oncological conditions. Procedures were conducted in a non-operating room anesthesia (NORA) setting. Procedural-related complications and short-term oncological outcomes were analyzed. Thirty-five patients (mean age 71.5 y, 80% male) were treated for HCC (26), CRLM (6) and gastric cancer metastases (3). Mean lesion size was 21 mm (SD ± 10.1 mm), and the most common tumor localization was the right hepatic lobe. RFA was performed in a step-up sedation approach, with subcutaneous lidocaine injection prior to needle placement and subsequent deep sedation during ablation. No anesthesia-related early or late complications occurred. One patient presented with pleural effusion due to a large ablation zone and was treated conservatively. Local tumor-free survival after 1 and 6 months was 100% in all cases where a curative RFA approach was intended. NORA for liver RFA comes with high patient acceptance and tolerance, and optimal postoperative outcomes and oncologic results.

Clinical audit of endoscopic sub-mucosal dissection performed for complex lateral spreading colorectal tumors from a region non-endemic for colorectal cancer.

Endoscopic resection is currently the treatment of choice for laterally spreading tumors (LSTs). Endoscopic sub-mucosal dissection (ESD) can achieve higher enbloc resection and R0 resection, albeit at a slightly higher risk of complications. Given scarce data on ESD from India, we performed a retrospective analysis of our experience with colorectal ESD (CR-ESD) to know its clinical efficacy and complications as well as to assess the learning curve of CR-ESD in non-endemic-areas. Retrospective analysis of prospectively maintained datasheet performed. All patients with large (>2cm), complex or recurrent colorectal LST who underwent ESD at our center between 2012 and 2021 were included in the study. Various baseline lesion-related parameters, procedure-related parameters, enbloc resection (ER) rates, R0 margins and adverse event rates were retrieved. CUSUM analysis was performed to calculate the minimum required procedures to achieve competency in CR-ESD. Total 149 patients were included in the study; mean patient age was 61.36±18.21 years. Most patients had lesions in rectum (n=102; 68.5%) followed by sigmoid colon (n=25; 16.8%). The mean lesion size was 46.62 ± 25.46 mm and the mean procedure duration for ESD was 219.30 ± 150.05 min. ER was achieved in 94.6% of lesions. R0 resection was achieved in 132 patients (88.6%). Overall, six (4%) adverse events were noted, of which one required surgical intervention.As many as 105patients (70.5%) had adenomatous lesions on histology. Seventy-four patients underwent follow-up colonoscopy, of which three had a recurrence of adenomatous lesions and five had post-resection stricture requiring endoscopic dilation. CUSUM curve analysis calculated the learning curve for ESD was 47 resections for ER and 55 for the occurrence of AEs, with a composite CUSUM at 47 procedures. CR-ESD even in non-endemic area is associated with high enbloc resection rates, R0 resection rates and acceptable complication profile. Approximately 50 cases of CR-ESD are required to achieve competency.

A Phase 2 Multicenter Clinical Trial of Intraoperative Molecular Imaging of Lung Cancer with a pH-Activatable Nanoprobe.

Intraoperative molecular imaging (IMI) uses tumor-targeted optical contrast agents to improve identification and clearance of cancer. Recently, a probe has been developed that only fluoresces when activated in an acidic pH, which is common to many malignancies. We report the first multicenter Phase 2 trial of a pH-activatable nanoprobe (pegsitacianine, ONM-100) for IMI of lung cancer. Patients with suspected or biopsy-confirmed lung cancer scheduled for sublobar resection were administered a single intravenous infusion of pegsitacianine (1mg/kg) one to three days prior to surgery. Intraoperatively, the patients underwent a white light thoracoscopic evaluation, and then were imaged with an NIR thoracoscope to detect tumor fluorescence. The primary study endpoint was the proportion of patients with a clinically significant event (CSE) which was defined as an intraoperative discovery during IMI that led to a change in the surgical procedure. Possible CSEs included (i) localizing the index lung nodule that could not be located by white light, (ii) identifying a synchronous malignant lesion, or (iii) recognizing a close surgical margin (< = 10mm). Secondary endpoints were sensitivity, specificity, NPV, and PPV of pegsitacianine in detecting tumor-containing tissue. The safety evaluation was based on adverse event reporting, clinical laboratory parameters, and physical examinations. Twenty patients were confirmed as eligible and administered pegsitacianine. Most of the patients were female (n = 12 [60%]), middle-aged (mean age 63.4years), and former smokers (n = 13 [65%], 28.6 mean pack years). Mean lesion size was 1.9cm, and most lesions (n = 17 [85%]) were malignant. The most common histologic subtype was adenocarcinoma (n = 9). By utilizing IMI with pegsitacianine, one patient had a CSE in the detection of a close margin and another had localization of a tumor not detectable by traditional surgical means. Six of 19 (31.6%) malignant lesions fluoresced with mean tumor-to-background ratio (TBR) of 3.00, as compared to TBR of 1.20 for benign lesions (n = 3). Sensitivity and specificity of pegsitacianine-based IMI for detecting malignant tissue was 31.6% and 33.3%, respectively. Positive predictive value (PPV) and negative predictive value (NPV) of pegsitacianine-based IMI was 75% and 7.1%, respectively. Pegsitacianine-based imaging was not effective in differentiating benign and malignant lymph nodes. From a safety perspective, no drug-related serious adverse events occurred. Four patients experienced mild pegsitacianine-related infusion reactions which required discontinuing the study drug with complete resolution of symptoms. Pegsitacianine-based IMI, though well tolerated from a safety perspective, does not consistently label lung tumors during resection and does not provide significant clinical benefit over existing standards of surgical care. The biology of lung tumors may not be as acidic as other solid tumors in the body thereby not activating the probe as predicted.